BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23034331)

  • 1. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
    Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F
    Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
    Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
    Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.
    Kato I; Niwa A; Heike T; Fujino H; Saito MK; Umeda K; Hiramatsu H; Ito M; Morita M; Nishinaka Y; Adachi S; Ishikawa F; Nakahata T
    PLoS One; 2011; 6(11):e27042. PubMed ID: 22069486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
    Sison EA; McIntyre E; Magoon D; Brown P
    Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
    Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
    PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
    Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
    Peled A; Tavor S
    Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
    Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
    Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
    Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
    Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.
    Kremer KN; Peterson KL; Schneider PA; Meng XW; Dai H; Hess AD; Smith BD; Rodriguez-Ramirez C; Karp JE; Kaufmann SH; Hedin KE
    J Biol Chem; 2013 Aug; 288(32):22899-914. PubMed ID: 23798675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
    Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
    Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
    Cho BS; Kim HJ; Konopleva M
    Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.
    Nervi B; Ramirez P; Rettig MP; Uy GL; Holt MS; Ritchey JK; Prior JL; Piwnica-Worms D; Bridger G; Ley TJ; DiPersio JF
    Blood; 2009 Jun; 113(24):6206-14. PubMed ID: 19050309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.
    Beider K; Begin M; Abraham M; Wald H; Weiss ID; Wald O; Pikarsky E; Zeira E; Eizenberg O; Galun E; Hardan I; Engelhard D; Nagler A; Peled A
    Exp Hematol; 2011 Mar; 39(3):282-92. PubMed ID: 21138752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
    Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
    Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
    Zhang Y; Saavedra E; Tang R; Gu Y; Lappin P; Trajkovic D; Liu SH; Smeal T; Fantin V; De Botton S; Legrand O; Delhommeau F; Pernasetti F; Louache F
    Sci Rep; 2017 Aug; 7(1):7305. PubMed ID: 28779088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.
    Kawaguchi A; Orba Y; Kimura T; Iha H; Ogata M; Tsuji T; Ainai A; Sata T; Okamoto T; Hall WW; Sawa H; Hasegawa H
    Blood; 2009 Oct; 114(14):2961-8. PubMed ID: 19657116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.
    Wang R; Feng W; Wang H; Wang L; Yang X; Yang F; Zhang Y; Liu X; Zhang D; Ren Q; Feng X; Zheng G
    Cancer Lett; 2020 Jan; 469():151-161. PubMed ID: 31669202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.